Compare PBK & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBK | BTAI |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 24.8M |
| IPO Year | 2024 | 2018 |
| Metric | PBK | BTAI |
|---|---|---|
| Price | $0.34 | $0.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 731.9K | ★ 9.6M |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $197.82 |
| Revenue Next Year | N/A | $910.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.07 |
| 52 Week High | $0.86 | $3.41 |
| Indicator | PBK | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 23.43 | 19.82 |
| Support Level | N/A | N/A |
| Resistance Level | $0.50 | $1.22 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 2.42 | 0.57 |
PowerBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.